Fig. 4: Kaplan-Meier survival curves for patients undergoing hepatectomy versus those who refused to undergo hepatectomy after neoadjuvant triple therapy (excluding 16 patients who lost the opportunity due to tumor progression). | Communications Medicine

Fig. 4: Kaplan-Meier survival curves for patients undergoing hepatectomy versus those who refused to undergo hepatectomy after neoadjuvant triple therapy (excluding 16 patients who lost the opportunity due to tumor progression).

From: Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)

Fig. 4: Kaplan-Meier survival curves for patients undergoing hepatectomy versus those who refused to undergo hepatectomy after neoadjuvant triple therapy (excluding 16 patients who lost the opportunity due to tumor progression).

a overall survival; b event-free survival. CI confidence interval; neoadjuvant triple therapy, neoadjuvant transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors.

Back to article page